サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1728238

抗精神病薬市場- 世界の産業規模、シェア、動向、機会、予測、用途別、薬剤分類別（第一世代、第二世代）、地域別、競合別、2020-2030年

Antipsychotic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Drug Classification (First Generation, Second Generation ), By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

抗精神病薬市場- 世界の産業規模、シェア、動向、機会、予測、用途別、薬剤分類別（第一世代、第二世代）、地域別、競合別、2020-2030年
出版日: 2025年05月16日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗精神病薬の世界市場は、2024年に152億9,000万米ドルと評価され、予測期間中にCAGR 8.88％で拡大し、2030年には254億8,000万米ドルに達すると予測されています。

同市場は、統合失調症、双極性障害、治療抵抗性うつ病などの深刻な精神疾患に対応する、医薬品分野の重要な構成要素としての役割を担っています。抗精神病薬は神経遮断薬としても知られ、脳内の神経伝達物質（主にドーパミン）の不均衡を標的とすることで、幻覚、妄想、気分不安定などの症状を管理・軽減するように設計されています。社会的なストレス要因やライフスタイルの変化に煽られ、精神疾患は世界的に増加しており、これらの薬物に対する需要はますます高まっています。世界保健機関（WHO）によると、2019年には世界のほぼ8人に1人が精神障害を抱えているといいます。COVID-19の流行はこの動向をさらに強め、不安やうつ病の症例が大幅に増加しました。認知度が高まり、偏見が薄れるにつれて、治療を求める人が増え、市場の拡大に寄与しています。抗精神病薬は進化を続け、有効性と忍容性を改善し、長期的な精神科医療と罹患患者のQOL向上に重要な役割を果たしています。

市場概要
予測期間 2026-2030
市場規模：2024年 152億9,000万米ドル
市場規模：2030年 254億8,000万米ドル
CAGR：2025年～2030年 8.88%
急成長セグメント 統合失調症
最大市場 北米

市場促進要因

精神疾患の有病率の上昇

主な市場課題

副作用

主要市場動向

個別化医療アプローチ

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の抗精神病薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 用途別（統合失調症、双極性障害、単極性障害、認知症、その他）
    • 薬剤分類別（第一世代（定型）、第二世代（非定型））
    • 企業別（2024）
    • 地域別
  • 市場マップ

第6章 北米の抗精神病薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州の抗精神病薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の抗精神病薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米の抗精神病薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの抗精神病薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Eli Lily and Company
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co, Ltd.
  • Pfizer Inc.
  • AbbVie Inc.
  • Dr. Reddy's Laboratories Limited
  • Otsuka Holdings Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 16327

The Global Antipsychotic Drugs Market was valued at USD 15.29 billion in 2024 and is projected to reach USD 25.48 billion by 2030, expanding at a CAGR of 8.88% during the forecast period. This market serves as a vital component of the pharmaceutical sector, addressing serious mental health disorders such as schizophrenia, bipolar disorder, and treatment-resistant depression. Antipsychotic medications, also known as neuroleptics, are designed to manage and reduce symptoms like hallucinations, delusions, and mood instability by targeting neurotransmitter imbalances, primarily dopamine, in the brain. With mental health conditions on the rise globally, fueled by societal stressors and lifestyle changes, demand for these drugs is escalating. According to the World Health Organization, nearly one in eight people worldwide were living with a mental disorder in 2019. The COVID-19 pandemic further intensified this trend, with significant increases in cases of anxiety and depression. As awareness grows and stigmas diminish, more individuals are seeking treatment, contributing to market expansion. Antipsychotics continue to evolve, offering improved efficacy and tolerability, and playing a key role in long-term psychiatric care and quality-of-life improvement for affected patients.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 15.29 Billion
Market Size 2030USD 25.48 Billion
CAGR 2025-20308.88%
Fastest Growing SegmentSchizophrenia
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Mental Health Disorders

The increasing global incidence of psychiatric conditions such as schizophrenia, bipolar disorder, and major depressive disorder is a primary growth driver for the antipsychotic drugs market. This rise is attributed to various factors including changing lifestyles, heightened stress levels, and improved diagnostic capabilities. Greater public awareness and reduced stigma around mental health are prompting more individuals to seek professional care. Consequently, this has led to higher diagnosis rates and an expanding patient population requiring pharmaceutical intervention. Antipsychotic drugs are essential in managing severe mental health symptoms, stabilizing patients, and preventing relapses. Their role in enhancing daily functioning and overall well-being has become increasingly prominent, aligning with the growing focus on holistic mental healthcare.

Key Market Challenges

Adverse Side Effects

A major challenge for the antipsychotic drugs market is the prevalence of adverse effects associated with these medications. Despite the advancements seen with second-generation (atypical) antipsychotics, many patients still experience side effects including significant weight gain, metabolic syndrome, sedation, and sexual dysfunction. These complications can hinder treatment adherence and diminish quality of life. Managing such side effects often requires additional medical oversight and therapeutic adjustments, which can increase healthcare costs and complicate patient care. This challenge underscores the importance of developing newer antipsychotic formulations with improved safety profiles to enhance patient compliance and long-term treatment outcomes.

Key Market Trends

Personalized Medicine Approach

The shift towards personalized medicine is a notable trend shaping the future of the antipsychotic drugs market. Leveraging pharmacogenomics, clinicians are now tailoring treatments to individual genetic profiles, enabling the selection of the most appropriate drug and dosage for each patient. This customized approach minimizes the risk of adverse effects and improves therapeutic efficacy. The integration of genetic testing and data-driven decision-making is helping to move beyond the traditional trial-and-error model, enhancing both clinical outcomes and patient satisfaction. As healthcare systems globally prioritize individualized care, personalized antipsychotic treatment strategies are expected to become a cornerstone in psychiatric therapy.

Key Market Players

  • Eli Lily and Company
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • AbbVie Inc.
  • Dr. Reddy's Laboratories Limited
  • Otsuka Holdings Co., Ltd.
  • Teva Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Antipsychotic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antipsychotic Drugs Market, By Application:

  • Schizophrenia
  • Bipolar Disorder
  • Unipolar Disorder
  • Dementia
  • Others

Antipsychotic Drugs Market, By Drug Classification:

  • First Generation (Typical)
  • Second Generation (Atypical)

Antipsychotic Drugs Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antipsychotic Drugs Market.

Available Customizations:

Global Antipsychotic Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antipsychotic Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, Others)
    • 5.2.2. By Drug Classification (First Generation (Typical), Second Generation (Atypical))
    • 5.2.3. By Company (2024)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Antipsychotic Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Drug Classification
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antipsychotic Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Drug Classification
    • 6.3.2. Mexico Antipsychotic Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Drug Classification
    • 6.3.3. Canada Antipsychotic Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Drug Classification

7. Europe Antipsychotic Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Drug Classification
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Antipsychotic Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Drug Classification
    • 7.3.2. Germany Antipsychotic Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Drug Classification
    • 7.3.3. United Kingdom Antipsychotic Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Drug Classification
    • 7.3.4. Italy Antipsychotic Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Drug Classification
    • 7.3.5. Spain Antipsychotic Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Drug Classification

8. Asia-Pacific Antipsychotic Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Drug Classification
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Antipsychotic Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Drug Classification
    • 8.3.2. India Antipsychotic Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Drug Classification
    • 8.3.3. South Korea Antipsychotic Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Drug Classification
    • 8.3.4. Japan Antipsychotic Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Drug Classification
    • 8.3.5. Australia Antipsychotic Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Drug Classification

9. South America Antipsychotic Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Drug Classification
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Antipsychotic Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Drug Classification
    • 9.3.2. Argentina Antipsychotic Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Drug Classification
    • 9.3.3. Colombia Antipsychotic Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Drug Classification

10. Middle East and Africa Antipsychotic Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Drug Classification
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Antipsychotic Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Drug Classification
    • 10.3.2. Saudi Arabia Antipsychotic Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Drug Classification
    • 10.3.3. UAE Antipsychotic Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Drug Classification

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Eli Lily and Company
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. AstraZeneca plc
  • 15.3. GlaxoSmithKline plc
  • 15.4. Johnson & Johnson
  • 15.5. Otsuka Pharmaceutical Co, Ltd.
  • 15.6. Pfizer Inc.
  • 15.7. AbbVie Inc.
  • 15.8. Dr. Reddy's Laboratories Limited
  • 15.9. Otsuka Holdings Co., Ltd.
  • 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendation

17. About Us & Disclaimer